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acute respiratory toxicity which, in combination with lack 
of prolonged CAR T cell persistence, resulted in the prema-
ture closure of the trial. Elevated levels of systemic IFNγ 
and IL-6 implied that the CEACAM5-specific T cells had 
undergone immune activation in vivo but only in patients 
receiving high-intensity pre-conditioning. Expression of 
CEACAM5 on lung epithelium may have resulted in this 
transient toxicity. Raised levels of serum cytokines includ-
ing IL-6 in these patients implicate cytokine release as 
one of several potential factors exacerbating the observed 
respiratory toxicity. Whilst improved CAR designs and T 
cell production methods could improve the systemic per-
sistence and activity, methods to control CAR T ‘on-target, 
off-tissue’ toxicity are required to enable a clinical impact 
of this approach in solid malignancies.
Keywords CEA · Chimeric antigen receptor · T cells · 
Toxicity · Persistence
Abstract The primary aim of this clinical trial was to 
determine the feasibility of delivering first-generation CAR 
T cell therapy to patients with advanced,  CEACAM5+ 
malignancy. Secondary aims were to assess clinical effi-
cacy, immune effector function and optimal dose of CAR 
T cells. Three cohorts of patients received increasing doses 
of  CEACAM5+-specific CAR T cells after fludarabine pre-
conditioning plus systemic IL2 support post T cell infusion. 
Patients in cohort 4 received increased intensity pre-condi-
tioning (cyclophosphamide and fludarabine), systemic IL2 
support and CAR T cells. No objective clinical responses 
were observed. CAR T cell engraftment in patients within 
cohort 4 was significantly higher. However, engraftment 
was short-lived with a rapid decline of systemic CAR T 
cells within 14 days. Patients in cohort 4 had transient, 
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Abbreviations
AE  Adverse event
CAR  Chimeric antigen receptor
CEA  Carcinoembryonic antigen (also CEACAM5; 
CD66e)
Col-1  Anti-collagen 1 antibody
CT  Computerized tomography
CTCAE  Common toxicity criteria for adverse events 
(version 3.0)
HAMA  Human anti-mouse antibody
MCP-1  Monocyte chemotactic protein-1
POD  Peroxidase
qPCR  quantitative polymerase chain reaction
SUSAR  Suspected unexpected serious adverse reaction
Introduction
CAR T cell technology has risen in prominence as a result 
of the durable, objective clinical responses reported in 
early phase trials testing CD19 CAR T cells against B cell 
leukaemia [1–6]. CAR’s typically consist of scFv tumour 
targeting domains fused to T cell signalling receptors 
that, when expressed in a T cell, can effectively re-direct 
immune effector activity towards the cell surface target 
antigen specified by the scFv domain and independent of 
HLA restriction [7–10]. Initial testing of CAR T cell ther-
apy against solid tumours has proven to be less efficacious 
[11–14]. These early clinical trials employed first-gener-
ation CAR technology and no patient pre-conditioning. 
Against this background, we conceived a trial design that 
questioned the role of CAR T cell dose and the relative 
intensity of patient pre-conditioning upon the function and 
clinical impact of adoptively transferred CAR T cells.
The tumour-associated antigen explored in this trial was 
carcinoembryonic antigen (CEA; CEACAM5; CD66e) 
which is expressed at high levels in a broad range of 
tumours including those of the gastrointestinal tract and has 
been extensively explored as a cancer vaccine target [15]. A 
phage-selected CEACAM5-specific scFv (MFE23), shown 
to be well tolerated in imaging and antibody-directed pro-
drug therapy strategies [16–18], was fused to CD3ζ to 
generate a first-generation CAR termed MFEζ that was 
extensively characterized for structure and function in T 
cell lines and primary human T cells [19–23]. The in vivo 
anti-tumour activity of anti-CEACAM5 CAR T cells [24] 
further supported a strategy of targeting CEACAM5 within 
the context of a clinical trial.
The trial proposal involved dose-escalation of CAR T 
cells within 3 cohorts to reach a maximum dose of 5 × 1010 
total T cells with fludarabine pre-conditioning and sys-
temic IL2 support. Subsequent cohorts were to receive the 
maximum dose of MFEζ CAR T cells combined with an 
increased intensity of pre-conditioning delivered by the com-
bination of cyclophosphamide and fludarabine [25]. The trial 
opened in 2007 after significant delays during the regulatory 
process due to issues reported in other immune-based trials 
[26, 27]. Fourteen patients were recruited prior to early ter-
mination due to transient acute toxicity after completion of 
cohort 4. We now report the clinical and scientific observa-
tions that confirm that intensity of pre-conditioning impacts 
upon the relative frequency but not absolute number of sys-
temic MFEζ CAR T cells. Furthermore, systemic cytokine 
data imply immune activation of first-generation MFEζ CAR 
T cells in vivo, whilst evidence of raised IL-6, paralleling 
that seen in CD19 CAR T cell trials targeting B cell leukae-
mia [5], putatively implies a common mechanism of in vivo 
CAR T activity that is dependent upon patient pre-condition-
ing and, potentially, all generations of CAR design.
Materials and methods
Trial design
This was a single-centre open-label, dose-escalation Phase 
I study (ClinicalTrials.gov identifier NCT01212887) man-
aged and conducted in accordance with the principles of 
Good Clinical Practice and UK legislative requirements 
(Medicines and Healthcare Regulatory Agency).
Primary objectives were to evaluate the feasibility of 
MFEζ CAR T cell therapy in patients with  CEACAM5+ 
tumours, to assess toxicity and to determine dose of MFEζ 
CAR T cells for optimal survival in the circulation. Second-
ary objectives were to assess functionality of MFEζ CAR 
T cells isolated from the circulation, to obtain preliminary 
evidence of radiological response and to evaluate safety.
The trial was based on a 3 + 3 design for cohorts 1 to 3 
and 4 + 3 for cohorts 4 and 5 (Table 2). If a dose-limiting 
toxicity was experienced, the cohort was to be expanded to 
six patients. All patients received pre-conditioning chemo-
therapy, MFEζ T cells then intravenous IL2 therapy. Patients 
in cohorts 1–3 received fludarabine chemotherapy (25 mg/
m2/day for 5 days) with inter-cohort escalation of MFEζ T 
cells. Patients in cohort 4 received maximum MFEζ T cell 
dose with cyclophosphamide (60 mg/kg/day for 2 days) prior 
to fludarabine (25 mg/m2/day for 5 days) chemotherapy. All 
patients received IV IL2 (600,000 IU/Kg 15-min infusion 
every 8 h maximum 12 doses). IL2 was commenced 90 min 
after MFEζ T cells. Criteria for IL2 dose delay, reduction 
or discontinuation defined within the protocol resulted in 
administration of a variable number of IL2 doses.
Inclusion criteria for this study included patients with 
advanced, histologically confirmed  CEACAM5+ malig-
nancy where standard curative or palliative measures 
were not applicable, ≥18 years old, life expectancy over 
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3 months, performance status of 0 or 1, adequate renal, 
cardiac, haematological and biochemical function. Exclu-
sion criteria included anti-cancer systemic treatment 
or radiotherapy within four weeks, on-going significant 
toxicity from previous therapies, brain metastases, sig-
nificant non-malignant disease (including autoimmune 
disease), prior BMT, previous extensive radiotherapy, 
current other malignancies and patients taking, or likely 
to require systemic steroids or other immunosuppressants.
Adverse event (AE) monitoring commenced from the 
point of written consent. AEs were reported as per Com-
mon Terminology Criteria for Adverse Events (CTCAE) 
Version 3.0. The following dose-limiting toxicities were 
defined when they were almost certainly or probably 
drug related; toxicity ≥grade 3 as a result of MFEζ T 
cells; toxicity caused by MFEζ T cells or chemotherapy 
preventing commencement of IL2 within 24 h; toxicity 
≥3 during IL2 therapy that did not resolve to ≤grade 2 
within 48 h of stopping IL2; toxicity ≥grade 3 as a result 
of chemotherapy despite optimal supportive medication 
excluding bone marrow suppression.
Patients were treated as inpatients and discharged 
home when clinically appropriate. They were followed 
up as outpatients and underwent computerized tomogra-
phy (CT) scans at 6 weeks, 3, 6 and 12 months which 
were reported to RECIST version 1.0.
Production of MFEζ CAR T cells
MFEζ CAR T cells were produced in compliance with 
Good Manufacturing Practice as previously described 
[28].
Blood collection, processing and cell counts
Blood samples were collected at pre-treatment, day 0 pre-
infusion, 2, 6 h, days 1, 2, 3, 4 and 5 post infusion and 
weeks 1, 2, 3, 4, 5, 6, 12 and then 12 weekly until off trial. 
Within 24 h of blood draw, plasma and PBMCs were iso-
lated from an EDTA blood at each time point following 
standard procedures and stored at −80 °C and in liquid 
nitrogen. An additional CPT™ Vacutainer tube [Becton–
Dickinson (BD), NJ, USA] was collected at each time point 
for mononuclear cells isolation and gDNA extraction using 
a  Wizard® Genomic DNA Purification Kit (Promega, WI, 
USA) following the manufacture’s protocol. Blood counts 
were collected daily during hospitalization and at each visit 
using a certified clinical haematology service. All sample 
processing and subsequent assays were performed in com-
pliance with good clinical laboratory practice guidelines 
and subjected to independent quality assurance control.
Laboratory assays
Real‑time PCR quantification of transduced cells
A validated quantitative PCR assay (qPCR) was devel-
oped to quantify the level of MFEζ CAR T cells in patient 
samples. A CAR-specific qPCR amplicon (MFEζ F 
primer 5′-CTTATTACTGCCAGCAAAGGAGTAGTT, 
R primer 5′-CAAAGCTCGCTCCGTCTGTAG, probe 
FAM-5′-CCCACTCACGTTCGGTGCTGGC) and 
genomic standard qPCR amplicon (b2 M, F primer 
5′-GGAATTGATTTGGGAGAGCATC, R primer 5′-CAG-
GTCCTGGCTCTACAATTTACTAA, probe FAM-5′-
AGTGTGACTGGGCAGATCATCCACCTTC) were used 
to determine total genome copies (b2 M) and transduced 
genome copies (MFEζ) per sample.
The assay was validated using a standard curve gen-
erated from a single-cell-cloned Jurkat-MFEζ cell line 
(100%) diluted to 10, 1, and 0.1% with non-transduced 
Jurkat gDNA. Each assay included a positive control of 
known transduction level (4%) and a non-transduced (0%) 
negative control. The acceptance criteria for the qPCR 
assay were set as Standard Curve R2 value ≥0.95, positive 
control = 4% (±2%) and lower limit of detection = 0.1% 
transduced cells.
IFNγ ELISA analysis
A 96-well ELISA plate was coated for 2 h at 37 °C or over-
night at 4 °C with 1 µg/ml IFNγ capture antibody (MAB-
285, R&D systems, MN, USA) and then washed with 
PBS + 0.05% Tween. IFNγ standards were then added 
(200–0.5 pg/ml) along with 10 and 100 µl patient plasma 
for each sample. Following incubation at 37 °C for 1 h, 
100 µl of biotinylated IFNγ detection antibody (BAF-285, 
R&D systems, MN, USA) was added to each well for a 
further hour at 37 °C. After three washes, Streptavidin per-
oxidase (POD) conjugate (Roche, Basel, Switzerland) was 
then added and the plate incubated at 37 °C for 30 min and 
then POD blue substrate (Roche, Basel, Switzerland) added 
for 30 min. The reaction was stopped by the addition of 
 H2SO4 and the plate read at 450 nm. The concentration of 
IFNγ was calculated using the standard curve.
Determination of cytokine concentrations in serum samples 
by Luminex bead array
Concentrations of plasma cytokines were measured using 
the Bio-Plex  Pro™ Human Cytokine 17-plex Assay kit 
(Bio-Rad Laboratories Inc, California, USA). Reconsti-
tuted standards, cytokine-specific coupled beads, detection 
antibodies and 50 µl of thawed serum samples were com-
bined according to manufacturer’s instructions and data 
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acquired with the Bio-Plex™ 200 reader (Bio-Rad Labo-
ratories Inc, California, USA). Data were analysed using 
Bio-Plex Manager™ software v6.0 (Bio-Rad Laboratories 
Inc, California, USA).
Anti‑mouse scFv assay
96-well microtiter plates were coated with MFE antibody 
(1 µg/ml in carbonate-bicarbonate buffer, 100 µl/well) 
for one hour at room temperature, washed with PBS and 
blocked with 5% Marvel/PBS/Tween solution (150 µl per 
well). After washing, the wells with incubated with either 
positive, negative control, PBS or patient samples diluted 
in 1% Marvel/PBS/Tween solution (1/100 dilution, 100 µl/
well) in four replicates for 1 h. The wells were washed and 
incubated with 100 µl per well of the appropriate secondary 
antibodies diluted in 1% Marvel/PBS/Tween solution. For 
the patient samples, rabbit anti-human IgG was added for 
1 h. The wells were washed and incubated with anti-rabbit 
HRP antibody (100 µl/well for 1 h). After washing, 100 µl/
well substrate (o-phenylenediamine in phosphate citrate 
buffer) was added and the reaction stopped after 5 min by 
adding 4 M hydrochloric acid (50 µl/well). The OD of the 
wells was obtained at 490 nm. The results were recorded as 
positive or negative according to previously set criteria for 
human anti-MFE antibody assay.
CEACAM5 expression in the lung
Following discontinuation of the clinical trial, we assessed 
whether the observed respiratory symptoms could have 
been attributable to CEACAM5 expression in the lungs of 
the patients. We accessed nine lung tissue samples from 
Manchester Cancer Research Centre Biobank. Eight were 
non-cancerous tissue from patients undergoing resec-
tion for lung cancer and the ninth was from a patient with 
metastatic colorectal cancer undergoing a lung resection. 
IHC using the Col-1 antibody [29] and qPCR were used to 
explore  CEACAM5+ expression in these samples.
Results
MFEζ trial background and recruitment
Of the twenty-three patients who gave informed consent, 
eight failed screening and one patient was ineligible due 
to disease progression prior to therapy. The remaining 14 
patients had a range of metastatic gastrointestinal malig-
nancies (Table 1). Each patient received pre-conditioning 
chemotherapy, MFEζ T cells and systemic IL2 support in 
4 cohorts (Table 2). The dose of MFEζ T cells received 
by patient 36007 in cohort 2 was lower than stipulated for 
full evaluation within the cohort so an additional patient 
(36009) was recruited as a replacement.
Clinical efficacy
No patients attained an objective response by RECIST 
although several had marked reduction in tumour mark-
ers. Seven patients achieved stable disease as their best 
response 6 weeks post MFEζ T cell infusion with 3 patients 
maintaining this response at 12 weeks (Table 2). There 
were no long-term sustained responses and thirteen patients 
died of progressive disease. One patient (36014) remained 
alive 56 months post infusion. This patient achieved dis-
ease stabilization as best response but progressed 155 days 
after baseline scan (127 days post T cell infusion) and went 
on to receive other therapy.
Increased intensity of pre‑conditioning chemotherapy 
improves the systemic engraftment but not absolute 
number of MFEζ CAR T cells
Patients in cohorts 1–3 experienced a transient decrease 
in whole blood counts (Supplementary Fig. 1a–c) lasting 
approximately one week with a period of lymphodepletion 
lasting 2–3 days with a nadir generally 1–2 days post cell 
infusion (Fig. 1a–c). Similar kinetics in monocyte and neu-
trophil counts were observed (Supplementary Fig. 2a–f). 
By contrast, patients in cohort 4 experienced a prolonged 
period of depressed blood counts (Supplementary Fig. 1d) 
and lymphopenia lasting approximately 10 days beginning 
2 days prior to cell infusion (Fig. 1d). Lymphocyte counts 
started to return towards normal levels from 10 days after 
cell infusion, a trend mirrored in the monocyte and neutro-
phil compartments although a rebound increase in both cell 
types was briefly observed during peripheral reconstitution 
(Supplementary Fig. 2g–h).
Molecular analysis of peripheral blood samples con-
firmed MFEζ engraftment levels in the region of 0.1–5% 
in cohorts 1–3 with a general trend of higher frequency of 
transduced cells correlating with infused cell dose across 
the cohorts (Fig. 1e–g). Engraftment levels peaked around 
day 6 before dropping to undetectable levels in 2 out of 3 
patients in cohort 1. After a peak of similar magnitude to 
cohort 1, only very low engraftment levels (in the region 
of 0.01%) were maintained in the majority of patients in 
cohorts 2 and 3 up to day 30. By contrast, patients in cohort 
4, despite receiving a wide range of T cell doses (range 
1.7 × 109–1.3 × 1010 total T cells, 20–37% transduced), all 
achieved much higher levels of MFEζ T cell engraftment at 
time points immediately after infusion reaching up to 60% 
within 5–10 days post infusion (Fig. 1h). However, as with 
earlier cohorts, a rapid drop off with no significant per-
sistence of MFEζ T cells observed two weeks after T cell 
Cancer Immunol Immunother 
1 3
transfer. Despite the percentage difference in CAR T cell 
engraftment, when the number of MFEζ T cell numbers 
were estimated by multiplying the fraction of transgene-
positive T cells from the qPCR data and the absolute lym-
phocyte counts, there was no significant difference in the 
absolute number of CAR cells between cohorts 3 and 4. 
This implies dissociation between intensity of pre-condi-
tioning and the absolute number of systemic CAR T cells 
albeit clearly within a limited number of patients within the 
two cohorts (Supplementary Fig. 3a–b).
Serum tumour markers and cytokine levels
Within cohorts 1–3, no significant reduction in serum CEA 
was seen at any stage during the trial except for a tran-
sient drop between MFEζ T cell infusion and week 4 for 
1 patient (36003; Fig. 2a). However, the three patients in 
cohort 4 who had significant baseline levels of soluble CEA 
(36013, 36015, 36017) were all found to have a reduction 
in levels post-infusion (Fig. 2b). In two patients (36013, 
36015), this level remained below that seen pre-infusion 
for at least 6 weeks. Six patients across all cohorts demon-
strated a transient reduction in CA19-9 levels post-infusion 
(Supplementary Fig. 4); however, responses were again 
short-lived. There was no obvious correlation between a 
biochemical response to therapy and clinical outcome.
In terms of systemic cytokine levels, patients within 
cohort 4 displayed peak levels of IFNγ, monocyte chem-
otactic protein-1 (MCP-1), IL-6, IL-8 and IL-10 on day 
7–14 correlating with peak frequency of MFEζ CAR T 
cell engraftment that returned to baseline at progression 
but with no effective modulation of the levels of IL-1β 
(Fig. 2c–h). Interestingly, the first patient treated (36003) 
with the lowest dose of T cells and fludarabine pre-condi-
tioning had a sustained systemic level of IFNγ (Fig. 2c), a 
suggestion of raised levels on day 7 of MCP-1 post-MFEζ 
Table 1  Patient demographics
S surgical resection of primary disease, RT palliative radiotherapy, Ir5FU irinotecan plus 5Fluorouracil, CapOx capecitabine plus oxaliplatin, 
Ox5FU oxaliplatin plus 5Fluorouracil, ECX epirubicin, cisplatin plus capecitabine, IrCap irinotecan plus capecitabine, EOX epirubicin, oxalipl-
atin plus capecitabine
Cohort Patient no (sequentially 
treated)
Sex Age Primary diagnosis 
(adenocarcinoma unless 
otherwise stated)
Metastatic sites WHO PS Previous treatment
1 36003 M 66 Colon Bone, liver, lung 1 S, RT right hip
Ir5FU, CapOx, Ox5FU, 
Ir5FU, Palliative RT R 
Hip
36004 M 47 Stomach Liver, lymph node 1 ECX, ECX rechallenge
36005 M 63 Rectum Liver, lung 1 S, CapOx, IrCap, Ir 
Cetuximab
2 36006 F 36 Pseudomyxoma peritonei Spleen 1 S, Mitomycin + Capecit-
abine 3 challenges
36007 M 53 Stomach Liver, lymph node 1 ECX
36008 F 49 Stomach Chest wall, liver, lymph 
node, peritoneum
0 S, ECX
36009 M 41 Rectum Bone, liver, lung 0 Ox5FU + Bevacizumab, 
5FU + Bevacizumab, 
Ir5FU + Bevacizumab, 
Ox5FU + Bevacizumab
3 36010 M 41 Oesophagus Lymph node 1 ECX
36011 M 49 Oesophagus Lymph node EOX
36012 F 42 Gastro-oesophageal 
junction
Liver, lung, lymph node 1 EOX
4 36013 F 40 Pancreas Liver, lung, peritoneum 1 S, RT local recurrence, 
GemCap, Capecitabine
36014 F 45 Colon Liver 0 S, metastasectomy (lung 
and liver), CapOx, 
Ir5FU, Ox5FU, IrCap.
36015 F 56 Colon Muscle, ovary,  
peritoneum,
0 S, Ox5FU
36017 M 40 Caecum Liver, lung 1 S, CapOx, Irinotecan
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and an apparent transient drop in serum CEA (Fig. 2a) with 
no other obvious elevation of other cytokines monitored.
Anti‑mouse scFv humoral immune response
Since anti-CAR transgene immune responses were impli-
cated in a previous CAR T cell trial [13], human anti-
mouse antibody (HAMA) responses were assessed. No 
HAMA response was seen in any patient above that of the 
pre-established lower limit of detection (Supplementary 
Fig. 5).
Preliminary evidence of MFEζ T cell trafficking 
into tumour sites
Fine needle biopsies taken from a restricted number of 
patients (36004, 36010, 26014 and 36017) were analysed 
for the presence of MFEζ T cells by qPCR with the fre-
quency of CAR T cells determined by comparison to the 
β2-microglobulin control. A strong MFEζ transgene sig-
nal detected in a tumour biopsy collected from patient 
36,004 was at much higher level than that detected in 
peripheral blood at an equivalent time point (Fig. 3). The 
MFEζ transgene signal was also detected in biopsy sam-
ples from patients 36014, 36015 and 36017 at higher levels 
than blood samples taken at the same time as the biopsies 
(Fig. 3). However, no specific signal was detected a biopsy 
taken from patient 36010. The limiting quantity of biopsy 
material restricted further analysis; however, these data 
suggest that MFEζ T cells possess some capacity to migrate 
into sites of tumour.
Adverse events
All patients experienced AEs with grade ≤2 events resolv-
ing within ten days. Patients in cohorts 1–3 experienced 
grade ≥3 level toxicities consistent with fludarabine and 
IL2 therapy (Supplementary Table 1). Patients in cohort 4 
experienced similar toxicities albeit with more pronounced 
grade and duration as anticipated for the level of pre-con-
ditioning chemotherapy. Each patient in this cohort also 
experienced additional AEs after cell transfer not read-
ily attributable to chemotherapy or IL2 (Supplementary 
Table 2). The first patient treated in cohort 4 (36013) devel-
oped grade 3 tachypnea and pulmonary infiltrates which 
resolved within 18 days (Fig. 4). Patient 36014 developed 
respiratory distress 5 days following T cell infusion and 
admitted to the critical care unit. All symptoms resolved 
as confirmed by a repeat CT scan one month later. Simi-
lar but less dramatic pulmonary toxicities were seen both of 
the subsequent patients in cohort 4 (36015 and 36017). The 
respiratory toxicity was managed conservatively with sup-
portive measures including high-flow oxygen. No patients 
required invasive ventilation and, whilst prophylactic anti-
biotics were given, there was no confirmation of respiratory 
infection and systemic steroids were not required. These 
events were all reported as a suspected unexpected serious 
adverse reaction (SUSAR). Three other SUSARs were also 
reported during the study including grade 3 neutropenic 
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Fig. 1  Increased intensity of patient pre-conditioning results in pro-
longed lymphodepletion and increased frequency of MFEζ CAR T 
cell engraftment. Lymphocyte counts (×109 cells/L) of patients in a 
cohort 1, b cohort 2, c cohort 3 and d cohort 4. The timing of fludara-
bine pre-conditioning (black box) and cyclophosphamide (grey box) 
are shown prior to MFEζ T cell infusion on day 0. MFEζ CAR T 
cell frequency determined by qPCR in blood samples estimated by 
comparison to β2-microglobulin to determine relative CAR T cell fre-
quency in e cohort 1, f cohort 2, g cohort 3 and h cohort 4
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sepsis (36013), grade 3 decreased appetite (36006) and 
grade 4 neutropenic sepsis and grade 2 intracranial haem-
orrhage in patient 36,008. AEs completely resolved within 
18 days.
At the completion of cohort 4, a safety review conducted 
by the trial sponsor concluded that the respiratory toxicities 
observed across all patients in cohort 4 posed an unfavourable 
risk benefit profile to patients. This toxicity combined with 
the lack of demonstrable clinical efficacy and the lack of sus-
tained CAR T cell engraftment in cohorts 1–4 suggested to 
the sponsor that achieving the primary endpoint of prolonged 
MFEζ T cell engraftment was unlikely to be met in subse-
quent cohorts. This resulted in the early closure of the study.
CEACAM5 expression in the lung
IHC identified two samples (W0076T1PNf and 
W0096T1PNc) as strongly positive with frequent 
 CEACAM5+ cells present and three intermediately posi-
tive (W00115T1PNd, W0098T1PNf and W00851PNc) 
with less frequent immuno-positive cells present which 
was confirmed by qPCR analysis (Supplementary Fig. 6). 
In the remaining three samples, there was either weak anti-
body staining or weak qPCR signal questioning the level 
of CEACAM5 expression in these samples (Supplemen-
tary Fig. 6). Thus, there appeared to be strong/intermedi-
ate CEACAM5 expression in 5/8 non-cancer lung resection 
samples. Interestingly, in one further lung resection sample 
(W0094T1PNc) from a patient with metastatic colorectal 
cancer, there was no qPCR signal at all for CEACAM5 and 
very low-level staining by the anti-collagen 1(Col-1) anti-
body (Supplementary Fig. 6).
Discussion
The primary end point of assessing the feasibility of deliv-
ering MFEζ CAR T cell therapy was achieved with all four-
teen eligible patients receiving pre-conditioning, CAR T 
cells and at least two doses of IL2. However, there were 
challenges in meeting the higher T cell dose required 
in cohorts 3 and 4 where the seven patients received 
0.9 ± 0.4 × 1010 T cells that was below the proposed maxi-
mum T cell dose of 5 × 1010 T cells. The GMP compliant 
production methods used in this trial were established over 
ten years ago [28] and current production methods includ-
ing bioreactor technology [30] now enable the routine 
production of high T cell numbers in manageable culture 
volumes.
Whilst the trial failed to identify a CAR T cell dose that 
resulted in long-term persistence of the MFEζ T cells, it 
did confirm that an increased intensity of pre-conditioning 
enhanced the relative frequency of CAR T cell engraft-
ment. Furthermore, the intensity of chemotherapy was also 
critical for CAR T cell function as cytokines pertinent to 
T cell activation were only consistently detected in cohort 
4. However, there was no obvious difference in the abso-
lute numbers of systemic MFEζ T cells suggesting a lack 
of in vivo CAR T cell expansion that is likely to adversely 
impact upon the therapeutic power of the approach.
Aside from sub-optimal culture technology, current evi-
dence suggests that second and subsequent generations 
of CARs can deliver increased potency of T cell signal-
ling, persistence and anti-tumour activity [10, 31, 32]. A 
recent report of hepatic artery infused second-generation 
CEACAM5-specific CAR T cells with systemic IL2 and 
no patient pre-conditioning reported tissue localization of 
the CAR T cells but no evidence of prolonged persistence 
and limited evidence of CAR T cell effector function albeit 
within the early stages of the overall clinical trial [33]. 
Undoubtedly, CD19 CAR T cells benefit from the ready 
access to  antigen+ leukaemic target cells resident within 
the periphery that can engage the CAR and help to drive T 
cell persistence. CAR T cells targeting solid tumour anti-
gens clearly require greater help which currently includes 
intensive pre-conditioning but will also require addi-
tional strategies to enhance localization and challenge the 
strongly immune-suppressive tumour microenvironment. 
More recent engineering strategies such as the armoured 
CAR approach [34] to alter the balance of immunity within 
the tumour potentially enhance clinical response.
A critical issue in this trial was the transient acute res-
piratory toxicity observed in patients within cohort 4 which 
combined with the lack of prolonged high levels of CAR T 
cell persistence and an absence of clinical response resulted 
in the early termination of the trial. Our expectation before 
opening of the trial was the potential for bowel toxicity due 
to the expression of CEACAM5 within the intestine [35] 
though no evidence of bowel-related toxicity was seen. 
We hypothesized that the respiratory symptoms observed 
in patients in cohort 4 may be indicative of ‘on-target off-
tumour’ MFEζ T cell binding to CEACAM5 antigen pre-
sent within the lung which would be consistent with the 
affinity (2.5 nM) of the MFE23 scFV [36] augmented by 
avidity in CAR T format. There are contradictory reports 
Fig. 2  Consistent decrease in systemic CEACAM5 levels and tran-
sient elevations in serum cytokines are seen in cohort 4 post-MFEζ 
CAR T cell infusion. Patients in each cohort are colour-coded to 
identify cohorts: cohort 1 in blue, cohort 2 in green, cohort 3 in red 
and cohort 4 in orange. Serum CEACAM5 levels were determined in 
patient blood samples prior and post-MFEζ CAR T cell infusion for 
a cohorts 1–3 and b cohort 4. The same colour-coding is applied to 
serum cytokine analysis of c IFNγ where analysis was performed at 
baseline (b) and weekly until day 28. For all other cytokines, d MCP-
1, e IL-6, f IL-8, g IL-10 and h IL-1β where baseline, day 7, day 14 
and post-treatment (P; day 21 or 28) are shown
◂
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in the literature with respect to CEACAM5 expression in 
normal lung with some documenting relatively high levels 
of CEACAM5 expression in normal lung tissue [37]; how-
ever, cross-reactivity of CEACAM5-specific monoclonal 
antibodies has raised questions whether the detected pro-
teins are CEACAM5 or related CEA-family members [29]. 
Our assessments demonstrated CEACAM5 expression in 
5 of 9 non-cancer lung resection samples supporting the 
hypothesis that MFEζ T cell binding to CEACAM5 anti-
gen present within normal lung may have contributed to 
this toxicity (Supplementary Fig. 6). A recent study inves-
tigating non-cancer tissue sections taken from patients with 
lung cancer identified the clear expression of CEACAM5 
as well as CEACAM1 and CEACAM6 family members in 
this non-cancer tissue [38]. This report also demonstrated 
that IFNγ up-regulates CEACAM5 expression on normal 
bronchiolar epithelial cells. Thus, CAR T cell activation 
may drive a local feedback loop through cytokine produc-
tion up-regulating CEACAM5 expression and driving local 
toxicity. This is consistent with the timing of the toxicity 
seen where no symptoms were manifest shortly after T cell 
infusion which would have been consistent with acute reac-
tion with pre-existing low levels of antigen as was seen in 
the acute death reported with a Her2-targeted CAR trial 
[39]. The delayed toxicity (peak around day 5–7 post infu-
sion) coinciding with peak of transduced T cells in the 
blood and the peak IFNγ is consistent with cytokine release 
and/or with delayed lung recognition because of increased 
MFEζ CAR T cells and/or up-regulation of CEACAM5 
as a result of exposure to IFNγ [38]. The delayed nature 
of the respiratory toxicity would also steer away from the 
likelihood of it being attributable solely to the IL2 and/or 
the pre-conditioning chemotherapy, although the possibility 
that one or both of these contributed cannot be excluded.
The transient nature of the toxicity may reflect the poor 
persistence of the MFEζ CAR T cells. Importantly, all 
cohort 4 patients were managed conservatively with sup-
portive measures only and no immune modulation such as 
steroids and yet fully recovered. Although the toxicity was 
transient, immune modulation may have reduced the sever-
ity of toxicity but also likely to reduce engraftment and effi-
cacy, thereby impacting upon the viability of the therapy.
Aside from IFNγ, cohort 4 patients also had elevated 
levels of IL-6, IL-8 and MCP-1 coupled with little modu-
lation of IL-1β that reflects observations made in B-ALL 
patients receiving CD19 CAR T cells [5]. This suggests that 
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Fig. 3  Molecular analysis of fine needle biopsy samples to deter-
mine the presence of MFEζ CAR T cells within tumour tissue. MFEζ 
transgene in tumour biopsies (hatched bars) and peripheral blood 
(black bars) taken at the same time as the biopsy at week 10 for pat-
ent 36004; week 6 for patient 36010; week 14 for patient 36014; 
week 6 for patient 36015; and week 4 for patient 36017
Fig. 4  Evidence of pulmonary infiltrates consistent with local cytokine release syndrome in patient 36,013. CT images demonstrating non-
specific pulmonary infiltrates 10 days after MFEζ T cell infusion (a) and resolution by day 42 (b)
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cytokine release including IL-6 can occur with the most 
basic CAR design and is dependent upon intensive pre-con-
ditioning regimes since no respiratory-related symptoms 
or elevated cytokine levels were seen in cohort 3 patients. 
In further experiments, we attempted to recapitulate this 
transient toxicity through the infusion of CEA transgenic 
mice with high doses of MFEζ CAR T cells combined with 
high dose IL2 (data not shown). There was no evidence of 
adverse toxicities observed in these animals illustrating the 
limitations of pre-clinical models to accurately model the 
human in vivo situation.
The lack of bowel toxicity in this trial contrasts with the 
severe colitis seen with T cells armed with TCR specific 
for CEACAM5 [40]. Presumably, this reflects the marked 
polarized expression of cell surface CEACAM5 that is only 
seen in the luminal surface of the bowel [35], thus making 
it relatively immune-protected from T cell cytotoxic activ-
ity as compared to the non-polarized expression profile of 
peptide-bound HLA molecules. The pulmonary toxicity in 
our trial serves to illustrate the challenges in isolating spe-
cific causes of toxicity in adoptive cell therapy where many 
will be multifactorial and inter-related and where there are 
multiple variables across different trials. These variables 
range from the pre-conditioning chemotherapy, IL2 regime 
(if used), variation in the scFv affinity for its target, dose of 
cells, manufacturing differences, to name but a few.
No significant treatment-related neurological toxicity 
was noted in this trial where all patients received a mod-
erate dose of fludarabine (25 mg/m2/day for 5 days) with 
first-generation CAR T cell therapy. However, there have 
been a number of reports of significant neurologic toxicities 
observed in CAR T cell trials. Notably a recent trial spon-
sored by Juno Therapeutics was halted after a number of 
patients died having developed cerebral oedema attributed 
initially to intensified lymphodepleting chemotherapy with 
fludarabine [41]. The trial was allowed to resume without 
the intensified chemotherapy, but this was not sufficient 
to ameliorate the toxicity as further patient deaths subse-
quently occurred. Whilst the significant toxicity observed 
in the Juno trial is not mirrored in our trial, the details of 
the mechanism of the toxicity will have an important influ-
ence on the direction for the field as a whole.
To conclude, this trial underlines the importance of pre-
conditioning chemotherapy for CAR T cell therapy and 
highlights the need to design CAR T cells to maximize the 
discrimination between high-level target expression within 
the tumour and low level within some normal tissues to 
avoid toxicity. The powerful avidity effect of CAR T cells 
means that lower affinity antibodies for CAR T cell ther-
apy may provide better discrimination between low-level 
expression on normal tissue and high level on the tumour. 
However, where such discrimination is not possible and 
clinical benefits are seen, approaches such as local steroids 
to manage on-target, off-tumour toxicity will be essential 
to fully explore the therapeutic potential of this approach in 
patients with solid tumours. CEACAM5 remains a poten-
tially useful target for CAR T cells with those caveats.
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